Annual CFI
-$134.00 M
+$2.86 B+95.52%
December 31, 2022
Summary
- As of March 3, 2025, HZNP annual cash flow from investing activities is -$134.00 million, with the most recent change of +$2.86 billion (+95.52%) on December 31, 2022.
- During the last 3 years, HZNP annual CFI has fallen by -$116.14 million (-650.41%).
Performance
HZNP Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFI
-$20.03 M
+$21.73 M+52.03%
June 30, 2023
Summary
- As of March 3, 2025, HZNP quarterly cash flow from investing activities is -$20.03 million, with the most recent change of +$21.73 million (+52.03%) on June 30, 2023.
- Over the past year, HZNP quarterly CFI has dropped by -$7.84 million (-64.40%).
Performance
HZNP Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFI
-$142.87 M
-$7.84 M-5.81%
June 30, 2023
Summary
- As of March 3, 2025, HZNP TTM cash flow from investing activities is -$142.87 million, with the most recent change of -$7.84 million (-5.81%) on June 30, 2023.
- Over the past year, HZNP TTM CFI has increased by +$88.98 million (+38.38%).
Performance
HZNP TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
HZNP Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +95.5% | -64.4% | +38.4% |
| 3 y3 years | -650.4% | +87.3% | +63.7% |
| 5 y5 years | -31.1% | -10000.0% | -700.1% |
HZNP Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +2134.4% | +64.4% | +145.0% | +17.3% | +1995.6% |
| 5 y | 5-year | +650.4% | +2134.4% | +64.4% | >+9999.0% | +700.1% | +2015.7% |
| alltime | all time | -584.6% | +2134.4% | -151.2% | >+9999.0% | -461.2% | +2015.7% |
Horizon Therapeutics Public Limited Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2023 | - | -$20.03 M(-52.0%) | -$142.87 M(+5.8%) |
| Mar 2023 | - | -$41.75 M(-14.9%) | -$135.03 M(+0.8%) |
| Dec 2022 | -$134.00 M(-95.5%) | -$49.07 M(+53.2%) | -$134.00 M(+10.0%) |
| Sep 2022 | - | -$32.02 M(+162.9%) | -$121.77 M(-47.5%) |
| Jun 2022 | - | -$12.18 M(-70.1%) | -$231.85 M(-24.1%) |
| Mar 2022 | - | -$40.72 M(+10.5%) | -$305.34 M(-89.8%) |
| Dec 2021 | -$2.99 B(+545.2%) | -$36.84 M(-74.1%) | -$2.99 B(-0.9%) |
| Sep 2021 | - | -$142.10 M(+65.9%) | -$3.02 B(+4.1%) |
| Jun 2021 | - | -$85.66 M(-96.9%) | -$2.90 B(-2.4%) |
| Mar 2021 | - | -$2.73 B(+4071.6%) | -$2.98 B(+541.1%) |
| Dec 2020 | -$464.07 M(+2498.8%) | -$65.43 M(+192.5%) | -$464.07 M(+12.9%) |
| Sep 2020 | - | -$22.37 M(-85.9%) | -$411.17 M(+4.6%) |
| Jun 2020 | - | -$158.07 M(-27.6%) | -$393.27 M(+67.9%) |
| Mar 2020 | - | -$218.20 M(+1641.2%) | -$234.21 M(+1211.6%) |
| Dec 2019 | -$17.86 M(-164.6%) | -$12.53 M(+180.5%) | -$17.86 M(-169.3%) |
| Sep 2019 | - | -$4.47 M(-550.8%) | $25.79 M(-34.8%) |
| Jun 2019 | - | $991.00 K(-153.6%) | $39.56 M(+2.8%) |
| Mar 2019 | - | -$1.85 M(-105.9%) | $38.47 M(+39.1%) |
| Dec 2018 | $27.65 M(-127.1%) | $31.11 M(+234.3%) | $27.65 M(-1580.4%) |
| Sep 2018 | - | $9.30 M(-9692.8%) | -$1.87 M(-86.2%) |
| Jun 2018 | - | -$97.00 K(-99.2%) | -$13.54 M(-88.1%) |
| Mar 2018 | - | -$12.66 M(-897.0%) | -$113.43 M(+11.0%) |
| Dec 2017 | -$102.19 M(-92.5%) | $1.59 M(-167.1%) | -$102.19 M(-89.1%) |
| Sep 2017 | - | -$2.37 M(-97.6%) | -$935.99 M(-0.2%) |
| Jun 2017 | - | -$99.98 M(+6926.1%) | -$937.56 M(+10.5%) |
| Mar 2017 | - | -$1.42 M(-99.8%) | -$848.81 M(-38.1%) |
| Dec 2016 | -$1.37 B | -$832.21 M(>+9900.0%) | -$1.37 B(+174.5%) |
| Sep 2016 | - | -$3.94 M(-64.9%) | -$499.29 M(-12.4%) |
| Jun 2016 | - | -$11.23 M(-97.9%) | -$569.66 M(-62.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | - | -$523.26 M(-1436.9%) | -$1.52 B(+52.4%) |
| Dec 2015 | -$995.05 M(+337.0%) | $39.14 M(-152.7%) | -$995.05 M(-7.9%) |
| Sep 2015 | - | -$74.31 M(-92.2%) | -$1.08 B(-8.9%) |
| Jun 2015 | - | -$958.44 M(>+9900.0%) | -$1.19 B(+418.9%) |
| Mar 2015 | - | -$1.44 M(-96.9%) | -$228.66 M(+0.4%) |
| Dec 2014 | -$227.72 M(+530.2%) | -$46.66 M(-74.1%) | -$227.72 M(+5.2%) |
| Sep 2014 | - | -$180.02 M(>+9900.0%) | -$216.55 M(+488.0%) |
| Jun 2014 | - | -$543.00 K(+9.9%) | -$36.83 M(+1.2%) |
| Mar 2014 | - | -$494.00 K(-98.6%) | -$36.40 M(+0.7%) |
| Dec 2013 | -$36.13 M(+2507.1%) | -$35.49 M(>+9900.0%) | -$36.13 M(+3636.8%) |
| Sep 2013 | - | -$298.00 K(+148.3%) | -$967.00 K(+40.6%) |
| Jun 2013 | - | -$120.00 K(-46.7%) | -$688.00 K(-53.5%) |
| Mar 2013 | - | -$225.00 K(-30.6%) | -$1.48 M(+6.6%) |
| Dec 2012 | -$1.39 M(-35.7%) | -$324.00 K(+1605.3%) | -$1.39 M(-44.9%) |
| Sep 2012 | - | -$19.00 K(-97.9%) | -$2.52 M(-20.4%) |
| Jun 2012 | - | -$910.00 K(+584.2%) | -$3.16 M(+40.7%) |
| Mar 2012 | - | -$133.00 K(-90.9%) | -$2.25 M(+4.3%) |
| Dec 2011 | -$2.15 M(-138.6%) | -$1.46 M(+119.5%) | -$2.15 M(+143.7%) |
| Sep 2011 | - | -$663.00 K(<-9900.0%) | -$884.00 K(+221.5%) |
| Jun 2011 | - | $5000.00(-112.2%) | -$275.00 K(-105.0%) |
| Mar 2011 | - | -$41.00 K(-77.8%) | $5.54 M(-0.6%) |
| Dec 2010 | $5.58 M(-1661.6%) | -$185.00 K(+242.6%) | $5.58 M(+4.0%) |
| Sep 2010 | - | -$54.00 K(-100.9%) | $5.36 M(-0.5%) |
| Jun 2010 | - | $5.82 M(<-9900.0%) | $5.39 M(-2308.2%) |
| Mar 2010 | - | -$6000.00(-98.5%) | -$244.00 K(-31.7%) |
| Dec 2009 | -$357.00 K(-54.6%) | -$400.00 K(+1438.5%) | -$357.00 K(-930.2%) |
| Sep 2009 | - | -$26.00 K(-113.8%) | $43.00 K(-37.7%) |
| Jun 2009 | - | $188.00 K(-258.0%) | $69.00 K(-158.0%) |
| Mar 2009 | - | -$119.00 K | -$119.00 K |
| Dec 2008 | -$786.00 K | - | - |
FAQ
- What is Horizon Therapeutics Public Limited annual cash flow from investing activities?
- What is the all time high annual CFI for Horizon Therapeutics Public Limited?
- What is Horizon Therapeutics Public Limited annual CFI year-on-year change?
- What is Horizon Therapeutics Public Limited quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Horizon Therapeutics Public Limited?
- What is Horizon Therapeutics Public Limited quarterly CFI year-on-year change?
- What is Horizon Therapeutics Public Limited TTM cash flow from investing activities?
- What is the all time high TTM CFI for Horizon Therapeutics Public Limited?
- What is Horizon Therapeutics Public Limited TTM CFI year-on-year change?
What is Horizon Therapeutics Public Limited annual cash flow from investing activities?
The current annual CFI of HZNP is -$134.00 M
What is the all time high annual CFI for Horizon Therapeutics Public Limited?
Horizon Therapeutics Public Limited all-time high annual cash flow from investing activities is $27.65 M
What is Horizon Therapeutics Public Limited annual CFI year-on-year change?
Over the past year, HZNP annual cash flow from investing activities has changed by +$2.86 B (+95.52%)
What is Horizon Therapeutics Public Limited quarterly cash flow from investing activities?
The current quarterly CFI of HZNP is -$20.03 M
What is the all time high quarterly CFI for Horizon Therapeutics Public Limited?
Horizon Therapeutics Public Limited all-time high quarterly cash flow from investing activities is $39.14 M
What is Horizon Therapeutics Public Limited quarterly CFI year-on-year change?
Over the past year, HZNP quarterly cash flow from investing activities has changed by -$7.84 M (-64.40%)
What is Horizon Therapeutics Public Limited TTM cash flow from investing activities?
The current TTM CFI of HZNP is -$142.87 M
What is the all time high TTM CFI for Horizon Therapeutics Public Limited?
Horizon Therapeutics Public Limited all-time high TTM cash flow from investing activities is $39.56 M
What is Horizon Therapeutics Public Limited TTM CFI year-on-year change?
Over the past year, HZNP TTM cash flow from investing activities has changed by +$88.98 M (+38.38%)